Skip to main content
SpringerLink
Log in

Antı-β2 Glycoprotein I Antibodies in Children with Rheumatologic Disorders

  • Original Research Article
  • Published:
Indian Journal of Clinical Biochemistry Aims and scope Submit manuscript

Abstract

Anti-beta-2-glycoprotein I antibodies (anti-β2GPI) which are the main antiphospholipid antibodies that characterize the autoimmune “antiphospholipid syndrome” are pathogenic and are contributing to thrombosis. We aimed to evaluate the presence and the diagnostic importance of these antibodies in children with different rheumatologic diseases with or without thrombosis risk. A total of 100 children with different rheumatologic diseases evaluated retrospectively. The mean anti-β2GPI IgG (p = 0.108), IgA (p = 0.547), and IgM (p = 0.807) levels showed no statistically significant difference between different diagnosis groups. But anti-β2GPI IgA and IgM levels were higher in SLE patient group. The mean anti-β2GPI IgG (p = 0.375), IgA (p = 0.811), and IgM (p = 0.276) levels were not also showed difference between disease groups with/without predisposition to thrombosis even though concentrations were higher in thrombosis group. In children with rheumatological complaints, anti-β2GPI antibody measurements should not be the first diagnostic criteria if vasculitis is not thought as the primary defect underlying the clinical symptoms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Groot PG, Meijers JC. β(2)-Glycoprotein I: evolution, structure, and function. J Thromb Haemost. 2011;9(7):1275–84.

    Article  Google Scholar 

  2. Nalli C, Piantoni S, Andreoli L, Motta M, Tincani A. Antiphospholipid syndrome and antiphospholipid antibodies in children: the two sides of the coin. Isr Med Assoc J. 2012;14(5):310–2.

    PubMed  Google Scholar 

  3. Schousboe I. β2-glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood. 1985;66(5):1086–91.

    CAS  PubMed  Google Scholar 

  4. Rioche M, Masseyeff R. Synthesis of plasma beta 2 glycoprotein I by human hepatoma cells in tissue culture. Biomedicine. 1974;21:420–3.

    CAS  PubMed  Google Scholar 

  5. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci. 1990;87:4120–4.

    Article  CAS  Google Scholar 

  6. Miyakis S, Lockshin MD, Atsumi M, Branch DW, Brey RL, Cervera R. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.

    Article  CAS  Google Scholar 

  7. Chamley LW, McKay EJ, Pattison NS. Cofactor dependent and cofactor independent anticardiolipin antibodies. Thromb Res. 1991;61(3):291–9.

    Article  CAS  Google Scholar 

  8. Asherson RA, Khamashta MA, Ordi-Ros J, Derksen RH, Machin SJ, Barquinero J, et al. The “primary” antiphospholipid syndrome; major clinical and serological features. Medicine. 1989;68:366–74.

    Article  CAS  Google Scholar 

  9. Alarcon-Segovia D, Deleze M, Oria CV, Sanchez-Guerrero J, Gomez-Pacheco L. Antiphospholipid antibodies and the anticardiolipin syndrome in SLE. A prospective analysis of 500 consecutive patients. Medicine. 1989;68:353–65.

    Article  CAS  Google Scholar 

  10. Avcin T, Silverman ED. Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome. Lupus. 2007;16:627–33.

    Article  CAS  Google Scholar 

  11. Lakos G, Favaloro EJ, Harris EN, Meroni PL, Tincani A, Wong RC, et al. International consensus guidelines on anticardiolipin and anti-beta2-glycoprotein I testing: report from the 13th international congress on antiphospholipid antibodies. Arthritis Rheum. 2012;64:1–10.

    Article  Google Scholar 

  12. de Laat B, Pengo V, Pabinger I, Musial J, Voskuyl AE, Bultink IE, et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost. 2009;7:1767–73.

    Article  Google Scholar 

  13. Shi W, Krilis SA, Chong BH, Gordon S, Chesterman CN. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust N Z J Med. 1990;20(3):231–6.

    Article  CAS  Google Scholar 

  14. Groot PG, Urbanus RT. The significance of autoantibodies against b2-glycoprotein I. Blood. 2012;120:266–74.

    Article  Google Scholar 

  15. Avcin T, Ambrozic A, Kuhar M, Kveder T, Rozman B. Anticardiolipin and anti-beta(2) glycoprotein I antibodies in sera of 61 apparently healthy children at regular preventive visits. Rheumatology. 2001;40(5):565–73.

    Article  CAS  Google Scholar 

  16. Asherson RA, Cervera R. Antiphospholipid antibodies, and infections. Ann Rheum Dis. 2003;62:388–93.

    Article  CAS  Google Scholar 

  17. Sene D, Piette JC, Cacoub P. Antiphospholipid antibodies, antiphospholipid syndrome, and infections. Autoimmun Rev. 2008;7(4):272–7.

    Article  CAS  Google Scholar 

  18. Blank M, Krause I, Fridkin M, Keller N, Kopolovic J, Goldberg I, et al. Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest. 2002;109(6):797–804.

    Article  CAS  Google Scholar 

  19. Loizou S, Singh S, Wypkema E, Asherson RA. Anticardiolipin, anti-beta(2)-glycoprotein I and antiprothrombin antibodies in black south African patients with infectious disease. Ann Rheum Dis. 2003;62:1106–11.

    Article  CAS  Google Scholar 

  20. Gabeta S, Norman GL, Gatselis N, Liaskos C, Papamichalis PA, Garagounis A, et al. IgA anti- B2GPI antibodies in patients with autoimmune liver diseases. J Clin Immunol. 2008;28:501–11.

    Article  CAS  Google Scholar 

  21. Mankai A, Achour A, Thabet Y, Manoubia W, Sakly W, Ghedira I. Anticardiolipin and anti-beta 2-glycoprotein I antibodies in celiac disease. Pathol Biol. 2012;60:291–5.

    Article  CAS  Google Scholar 

  22. Borges RB, Bodanese LC, Muhlen CA, Repetto G, Viehe M, Norman GL, et al. Anti-beta2-glycoprotein I autoantibodies and metabolic syndrome. Arq Bras Cardiol. 2011;96:272–6.

    Article  CAS  Google Scholar 

  23. Serrano A, Garcia F, Serrano M, Ramirez E, Alfaro FJ, Lora D, et al. IgA antibodies against beta2 glycoprotein I in hemodialysis patients are an independent risk factor for mortality. Kidney Int. 2012;81:1239–44.

    Article  CAS  Google Scholar 

  24. Petri M. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb Res. 2004;114:593–5.

    Article  CAS  Google Scholar 

  25. Tubach F, Hayem G, Marchand JL, Weber M, Palazzo E, de Bandt M, et al. IgG anti-beta-2-glycoprotein I antibodies in adult patients with systemic lupus erythematosus: prevalence and diagnostic value for the antiphospholipid syndrome. J Rheumatol. 2000;27:1437–43.

    CAS  PubMed  Google Scholar 

  26. Long AA, Ginsberg JS, Brill-Edwards P, Johnston M, Turner C, Denburg JA, et al. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study. Thromb Haemost. 1991;66:520–4.

    Article  CAS  Google Scholar 

  27. Sebastiani GD, Passiu G, Galeazzi M, Porzio F, Carcassi U. Prevalence and clinical associations of anticardiolipin antibodies in systemic lupus erythematosus: a prospective study. Clin Rheumatol. 1991;10:289–93.

    Article  CAS  Google Scholar 

  28. Gupta R, Thabah MM, Gupta S, Shankar S, Kumar A. Clinical significance of antiphospholipid antibodies in Indian scleroderma patients. Rheumatol Int. 2009;30:277–9.

    Article  CAS  Google Scholar 

  29. Pasoto SG, Chakkour HP, Natalino RR, Viana VS, Bueno C, Lianza AC, et al. Lupus anticoagulant: a marker for stroke and venous thrombosis in primary Sjögren’s syndrome. Clin Rheumatol. 2012;31:1331–8.

    Article  Google Scholar 

  30. Olech E, Merrill JT. The prevalence and clinical significance of antiphospholipid antibodies in rheumatoid arthritis. Curr Rheumatol Rep. 2006;8(2):100–8.

    Article  CAS  Google Scholar 

  31. Avcin T, Cimaz R, Silverman ED, Cervera R, Gattorno M, Garay S, et al. Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. Pediatrics. 2008;122:e1100–7.

    Article  Google Scholar 

  32. Mehrani T, Petri M. IgM anti-beta2 glycoprotein I is protective against lupus nephritis and renal damage in systemic lupus erythematosus. J Rheumatol. 2011;38:450–3.

    Article  Google Scholar 

  33. Sweiss NJ, Bo R, Kapadia R, Manst D, Mahmood F, Adhikari T, et al. IgA anti-beta2-glycoprotein I autoantibodies are associated with an increased risk of thromboembolic events in patients with systemic lupus erythematosus. PLoS ONE. 2010;5(8):e12280.

    Article  Google Scholar 

  34. de Laat B, de Groot PG, Derksen RH, Urbanus RT, Mertens K, Rosendaal FR, et al. Association between beta2-glycoprotein I plasma levels and the risk of myocardial infarction in older men. Blood. 2009;114:3656–61.

    Article  Google Scholar 

  35. Gropp K, Weber N, Reuter M, Micklisch S, Kopka I, Hallstrom T, et al. Beta(2)-glycoprotein I, the major target in antiphospholipid syndrome, is a special human complement regulator. Blood. 2011;118:2774–83.

    Article  CAS  Google Scholar 

  36. Lin F, Murphy R, White B, Kelly J, Feighery C, Doyle R, et al. Circulating levels of b2-glycoprotein I in thrombotic disorders and in inflammation. Lupus. 2006;15:87–93.

    Article  CAS  Google Scholar 

Download references

Funding

This research received no specific grant from any funding agency in the public, commercial, or not—for—profit sectors.

Author information

Authors and Affiliations

  1. Department of Pediatric Immunology, Faculty of Medicine, Ege University, 35040, Bornova, Izmir, Turkey

    Elif Azarsiz, Gamze Eman, Sanem Eren Akarcan, Ezgi Ulusoy Severcan, Neslihan Karaca, Guzide Aksu & Necil Kutukculer

Authors
  1. Elif Azarsiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gamze Eman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sanem Eren Akarcan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ezgi Ulusoy Severcan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Neslihan Karaca
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Guzide Aksu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Necil Kutukculer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elif Azarsiz.

Ethics declarations

Conflict of interest

The Authors declared that they have no conflict of interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Azarsiz, E., Eman, G., Akarcan, S.E. et al. Antı-β2 Glycoprotein I Antibodies in Children with Rheumatologic Disorders. Ind J Clin Biochem 34, 95–100 (2019). https://doi.org/10.1007/s12291-017-0711-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12291-017-0711-0

Keywords

Search

Navigation